Your browser doesn't support javascript.
loading
21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?
Oppong, Bridget A; Sen Gupta, Surupa; Gary, Monique; Wehner, Patricia; Mete, Mihriye; Zhao, Danjing; Seevaratnam, Sulakshana; Rudra, Sonali; Willey, Shawna C.
Afiliación
  • Oppong BA; Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Sen Gupta S; Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Gary M; Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Wehner P; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA.
  • Mete M; Department of Biostatics, MedStar Health Research Institute, Hyattsville, MD, USA.
  • Zhao D; Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA.
  • Seevaratnam S; Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
  • Rudra S; Department of Radiation Oncology, MedStar Georgetown University, Washington, DC, USA.
  • Willey SC; Department of Surgery, MedStar Georgetown University Hospital, Washington, DC, USA.
Gland Surg ; 6(6): 675-681, 2017 Dec.
Article en En | MEDLINE | ID: mdl-29302485
BACKGROUND: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC. METHODS: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013-2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy. RESULTS: The mean age was 68 years. Tumors were stage Ia (86.6%), 3.6% Ib and 9.8% IIa. Of 50 patients (61.0%) with RS testing, 72% (n=36) were low risk (RS 0-17), with 28% (n=14) at intermediate risk (RS 18-30). The 39% (n=32) of patients without RS testing, were more likely to have smaller tumors (1.3 vs. 0.9 cm) and age >70 (P<0.05). CONCLUSIONS: Most patients selected for IORT based on clinical features were indeed low risk based on RS. Given the limited long-term clinical outcome and safety data of this technique, additional investigation is needed.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gland Surg Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Gland Surg Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: China